NCT06698666RecruitingPhase 3
Efficacy of Statins Among Major Depressive Disorder
The Efficacy of Statins in Management of Major Depression Disorder (MDD) Among Adult Patients Attending the Outpatient Clinics of El Demerdash Hospital.
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if drug Rosuvastatin 10 mg works to treat MDD in adults. It will also learn about the safety of Rosuvastatin 10 mg .The main questions it aims to answer are: Does Rusovastatin lower the score of The Montgomery Asberg Depression Rating Scale (MADRS) among adult participants with Major Depression Disorder ( MDD )? What medical problems do participants have when taking drug ABC? Participants will: Take Rosuvastatin 10 mg every day for 3 months Visit the clinic once every 4 weeks for checkups and tests Report any side effects for Rosuvastatin 10 mg and reassess the severity of depression using The Montgomery Asberg Depression Rating Scale (MADRS)
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 145 (estimated)
- First submitted
- 18 Nov 2024
- Start date
- 1 Oct 2022
- Primary completion date
- 4 Dec 2024
- Lead sponsor
- Ain Shams University
- Diseases
- Depression
- NCT number
- NCT06698666
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 145
- From 1 Oct 2022 to the primary completion date, 4 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current regular use of statins, corticosteroids, or any other immunomodulatory agents; and
Other illness
- lifetime or current SCID-I/P diagnosis of a psychotic disorder;
- lifetime SCID-I/P diagnosis of bipolar I or II disorder or alcohol dependence;
- acute or unstable systemic medical disorder;
- history of intolerance or allergy to study medications;
Other
- inability to comply with the requirements of informed consent or the study protocol;
- Current pregnancy or breast feeding;
- Females on Contraception.
Who the study is looking for
- aged between 20 and 45 years;
- diagnosis of current MDD, verified using the Structured Clinical Interview for DSM-IV Axis I Disorders, patient version (SCID-I/P);
- The Montgomery Asberg Depression Rating Scale (MADRS) score of 7 to 34, indicating mild to moderate depression;
- the ability to give informed consent and to comply with standard procedures;
- Males and females; and
- Stable pharmacological treatment for at least 2 weeks prior to enrolment (changes to medication dose or frequency of therapy excepted) if currently being treated.
Age in the registry: 20 years to 45 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| El-Demerdash hospital | Cairo | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.